Log in

NYSE:AVNSAvanos Medical Stock Price, Forecast & News

$30.34
+0.32 (+1.07 %)
(As of 07/3/2020 04:00 PM ET)
Add
Compare
Today's Range
$29.98
Now: $30.34
$31.16
50-Day Range
$26.21
MA: $28.95
$33.86
52-Week Range
$19.46
Now: $30.34
$48.07
Volume272,965 shs
Average Volume350,184 shs
Market Capitalization$1.45 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.19
Avanos Medical, Inc. operates as a medical technology company that focuses on delivering medical device solutions to improve patients' quality of life worldwide. It provides a portfolio of products focuses on respiratory and digestive health; pain management solutions; and minimally invasive interventional pain therapies, closed airway suction systems, and enteral feeding tubes. The company also offers Game Read, a product for pain management and rehabilitation of patients recovering from orthopedic surgery or sports-related injuries; GRPro 2.1, a cold and compression therapy system; Med4Elite, a multi-modality therapy unit; ATX Wraps; and various product accessories. In addition, it sells its products under the ON-Q, COOLIEF, MICROCUFF, MIC-KEY, HOMEPUMP, CORTRAK, and GAME READY brand names. The company markets its products directly to hospitals and other healthcare providers, as well as through third-party distribution channels. The company was formerly known as Halyard Health, Inc. and changed its name to Avanos Medical, Inc. in June 2018. Avanos Medical, Inc. was incorporated in 2014 and is headquartered in Alpharetta, Georgia.
Read More
Avanos Medical logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.1Community Rank: 2.1Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 1.9 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.01 out of 5 stars


Industry, Sector and Symbol

Industry Surgical appliances & supplies
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone844-428-2667

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$697.60 million
Cash Flow$1.83 per share
Book Value$26.40 per share

Profitability

Net Income$-45,900,000.00

Miscellaneous

Employees4,700
Market Cap$1.45 billion
Next Earnings Date8/4/2020 (Estimated)
OptionableOptionable

Receive AVNS News and Ratings via Email

Sign-up to receive the latest news and ratings for AVNS and its competitors with MarketBeat's FREE daily newsletter.

Avanos Medical (NYSE:AVNS) Frequently Asked Questions

How has Avanos Medical's stock been impacted by COVID-19 (Coronavirus)?

Avanos Medical's stock was trading at $29.01 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, AVNS stock has increased by 4.6% and is now trading at $30.34. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Avanos Medical?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Avanos Medical in the last year. There are currently 1 sell rating, 4 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Avanos Medical.

When is Avanos Medical's next earnings date?

Avanos Medical is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Avanos Medical.

How were Avanos Medical's earnings last quarter?

Avanos Medical Inc (NYSE:AVNS) announced its earnings results on Wednesday, May, 6th. The company reported $0.16 earnings per share for the quarter, hitting analysts' consensus estimates of $0.16. The business earned $180.40 million during the quarter, compared to analysts' expectations of $175.15 million. Avanos Medical had a negative net margin of 3.07% and a positive return on equity of 4.09%. The business's revenue for the quarter was up 9.9% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.15 earnings per share. View Avanos Medical's earnings history.

What price target have analysts set for AVNS?

7 brokers have issued twelve-month price objectives for Avanos Medical's shares. Their forecasts range from $30.00 to $48.00. On average, they anticipate Avanos Medical's stock price to reach $36.00 in the next twelve months. This suggests a possible upside of 18.7% from the stock's current price. View analysts' price targets for Avanos Medical.

Has Avanos Medical been receiving favorable news coverage?

Press coverage about AVNS stock has been trending negative this week, according to InfoTrie Sentiment. The research firm scores the sentiment of press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Avanos Medical earned a news impact score of -2.8 on InfoTrie's scale. They also gave headlines about the company a news buzz of 7.0 out of 10, meaning that recent press coverage is likely to have an effect on the company's share price in the next few days. View the latest news about Avanos Medical.

Are investors shorting Avanos Medical?

Avanos Medical saw a drop in short interest in the month of June. As of June 15th, there was short interest totaling 2,370,000 shares, a drop of 13.8% from the May 31st total of 2,750,000 shares. Based on an average daily trading volume, of 430,000 shares, the short-interest ratio is presently 5.5 days. Currently, 5.1% of the company's stock are short sold. View Avanos Medical's Current Options Chain.

Who are some of Avanos Medical's key competitors?

What other stocks do shareholders of Avanos Medical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Avanos Medical investors own include Kimberly Clark (KMB), AT&T (T), Alibaba Group (BABA), CVS Health (CVS), Honeywell International (HON), Procter & Gamble (PG), Verizon Communications (VZ), Home Depot (HD), Johnson & Johnson (JNJ) and Altria Group (MO).

Who are Avanos Medical's key executives?

Avanos Medical's management team includes the following people:
  • Mr. Joseph F. Woody, CEO & Director (Age 53)
  • Mr. John W. Wesley, Sr. VP of Legal & Gov. Relations (Age 60)
  • Mr. John R. Tushar, Pres of Global Franchises (Age 57)
  • Mr. Arjun Ranjan Sarker, Sr. VP of International (Age 53)
  • Mr. Warren J. MacHan, Sr. VP of Bus. Strategy & Interim CFO (Age 53)

What is Avanos Medical's stock symbol?

Avanos Medical trades on the New York Stock Exchange (NYSE) under the ticker symbol "AVNS."

Who are Avanos Medical's major shareholders?

Avanos Medical's stock is owned by many different retail and institutional investors. Top institutional investors include Confluence Investment Management LLC (1.16%). Company insiders that own Avanos Medical stock include Gary Blackford, John W Wesley, Joseph Fralin Woody and Steven E Voskuil. View institutional ownership trends for Avanos Medical.

Which major investors are selling Avanos Medical stock?

AVNS stock was sold by a variety of institutional investors in the last quarter, including Confluence Investment Management LLC. View insider buying and selling activity for Avanos Medical.

How do I buy shares of Avanos Medical?

Shares of AVNS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Avanos Medical's stock price today?

One share of AVNS stock can currently be purchased for approximately $30.34.

How big of a company is Avanos Medical?

Avanos Medical has a market capitalization of $1.45 billion and generates $697.60 million in revenue each year. The company earns $-45,900,000.00 in net income (profit) each year or $1.07 on an earnings per share basis. Avanos Medical employs 4,700 workers across the globe.

What is Avanos Medical's official website?

The official website for Avanos Medical is avanos.com.

How can I contact Avanos Medical?

Avanos Medical's mailing address is 5405 Windward Parkway Suite 100 South, Alpharetta GA, 30004. The company can be reached via phone at 844-428-2667 or via email at [email protected]

This page was last updated on 7/4/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.